- Home
- SMSI vs TRAW Comparison
SMSI vs TRAW Comparison
Compare SMSI & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- TRAW
- Stock Information
- Founded
- SMSI 1982
- TRAW 1998
- Country
- SMSI United States
- TRAW United States
- Employees
- SMSI N/A
- TRAW N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- TRAW
- Sector
- SMSI Technology
- TRAW
- Exchange
- SMSI Nasdaq
- TRAW NYSE
- Market Cap
- SMSI 24.7M
- TRAW 22.7M
- IPO Year
- SMSI 1995
- TRAW 2013
- Fundamental
- Price
- SMSI $1.39
- TRAW $4.48
- Analyst Decision
- SMSI Strong Buy
- TRAW
- Analyst Count
- SMSI 1
- TRAW 0
- Target Price
- SMSI $5.00
- TRAW N/A
- AVG Volume (30 Days)
- SMSI 208.7K
- TRAW 51.3K
- Earning Date
- SMSI 03-04-2025
- TRAW 03-31-2025
- Dividend Yield
- SMSI N/A
- TRAW N/A
- EPS Growth
- SMSI N/A
- TRAW N/A
- EPS
- SMSI N/A
- TRAW N/A
- Revenue
- SMSI $24,178,000.00
- TRAW $226,000.00
- Revenue This Year
- SMSI N/A
- TRAW $3.81
- Revenue Next Year
- SMSI $53.43
- TRAW N/A
- P/E Ratio
- SMSI N/A
- TRAW N/A
- Revenue Growth
- SMSI N/A
- TRAW N/A
- 52 Week Low
- SMSI $0.52
- TRAW $4.06
- 52 Week High
- SMSI $5.04
- TRAW $27.50
- Technical
- Relative Strength Index (RSI)
- SMSI 52.63
- TRAW 30.18
- Support Level
- SMSI $1.33
- TRAW $4.40
- Resistance Level
- SMSI $1.55
- TRAW $7.49
- Average True Range (ATR)
- SMSI 0.13
- TRAW 0.75
- MACD
- SMSI -0.01
- TRAW -0.34
- Stochastic Oscillator
- SMSI 43.48
- TRAW 1.90
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.